Obesity medicine s foggy future is getting clearer newsday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsday.com Daily Mail and Mail on Sunday newspapers.
The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's highly-effective Zepbound, but Amgen is taking a unique approach. Zepbound, which promotes the most weight loss among treatment options currently on the market, stimulates two different gut hormones to fight obesity, GLP-1 and GIP. Amgen's most advanced experimental candidate activates GLP-1 while blocking GIP.
California pharma company Amgen is betting on its weight loss shots that appear to help people drop pounds and keep them off for longer than a weekly dose of Wegovy or Zepbound would.